Company Structure Therapeutics Inc.

Equities

GPCR

US86366E1064

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 21:00:00 24/05/2024 BST			5-day change	1st Jan Change
37.06 ^USD	-3.29%		+2.52%	-9.08%

05-21	JPMorgan Starts Structure Therapeutics With Overweight Rating	MT
05-09	Structure Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases. It is focused on G-protein coupled receptors (GPCRs) as a therapeutic target class. Its product candidates include GSBR-1290, Amylin, glucose-dependent insulinotropic polypeptide receptor (GIPR), GCGR, ANPA-0073 and LTSE-2578. It is developing GSBR-1290, its oral small molecule product candidate targeting the validated glucagon-like-peptide-1 receptor (GLP-1R) for the treatment of type 2 diabetes mellitus (T2DM) and obesity. It is developing GLP-1R candidates, including dual GLP-1R/GIPR agonists and amylin agonists, each designed with customized properties to achieve additional benefit. It is developing ANPA-0073, an investigational oral small molecule APJR agonist, for the treatment of idiopathic pulmonary fibrosis (IPF). It is evaluating its LPA1R program, LTSE-2578 for IPF and progressive pulmonary fibrosis.

Number of employees: 93

Managers	Title	Age	Since
Raymond Stevens FOU	Founder	60	31/01/19
Jun Yoon DFI	Director of Finance/CFO	46	31/01/19
Ying Li Ma CTO	Chief Tech/Sci/R&D Officer	50	31/07/22
Xi Chen Lin CTO	Chief Tech/Sci/R&D Officer	50	30/06/19
Mark Bach CTO	Chief Tech/Sci/R&D Officer	67	31/05/21
Lani Ibarra CTO	Chief Tech/Sci/R&D Officer	-	-
Tony Peng LAW	General Counsel	-	-
Karen S. Wright AUD	Comptroller/Controller/Auditor	69	-

Members of the board	Title	Age	Since
Sharon Tetlow BRD	Director/Board Member	64	28/03/22
Ted Love BRD	Director/Board Member	65	02/08/23
Eric Dobmeier BRD	Director/Board Member	55	30/11/22
Daniel Welch CHM	Chairman	66	18/01/22
Ramy Farid BRD	Director/Board Member	59	31/03/19
Raymond Stevens FOU	Founder	60	31/01/19
Jun Yoon DFI	Director of Finance/CFO	46	31/01/19
Joanne Waldstreicher BRD	Director/Board Member	63	30/11/22

	Vote	Quantity	Free-Float	Total Float
Stock A	0	2,161	0	76.06 %
Stock B	0	32,857	0
Stock C	1	139,794,124	106,321,015 ( 76.06 %)
Stock D	0	12,800	0
Stock E	0	19,200	0

Name	Equities	%	Valuation
Wellington Management Co. LLP 12.51 %	5,827,656	12.51 %	227 M $
Wellington Management Co. LLP 9.408 %	4,383,960	9.408 %	171 M $
Fidelity Management & Research Co. LLC 6.253 %	2,913,862	6.253 %	114 M $
Driehaus Capital Management LLC 5.344 %	2,490,303	5.344 %	97 M $
Federated Global Investment Management Corp. 4.844 %	2,257,206	4.844 %	88 M $
Janus Henderson Investors US LLC 4.457 %	2,076,700	4.457 %	81 M $
TCG Crossover Management LLC 3.430 %	1,598,421	3.430 %	62 M $
T Rowe Price Associates, Inc. (13F Subfiler) 3.350 %	1,560,950	3.350 %	61 M $
Capital Research & Management Co. (Global Investors) 3.278 %	1,527,483	3.278 %	60 M $
RA Capital Management LP 3.241 %	1,510,362	3.241 %	59 M $

Name	Equities	%	Valuation
BVF Partners LP 3.701 %	5,173,941	3.701 %	67 M $
Qiming Venture Partners Ltd. 3.534 %	4,941,022	3.534 %	64 M $
Ramy Farid 2.923 %	4,085,495	2.923 %	53 M $
Chen-Ming Yu 2.474 %	3,458,242	2.474 %	45 M $
Raymond Stevens 1.882 %	2,630,250	1.882 %	34 M $
Jun Yoon 1.874 %	2,620,050	1.874 %	34 M $
Impresa Management LLC 0.4120 %	575,934	0.4120 %	7 M $
Daniel Welch 0.0883 %	123,508	0.0883 %	2 M $
Ying Li Ma 0.0263 %	36,729	0.0263 %	477 184 $
Mark Bach 0.003090 %	4,320	0.003090 %	56 126 $

Structure Therapeutics, Inc.

601 Gateway Boulevard Suite 900

94080, South San Francisco

http://www.structuretx.com

address Structure Therapeutics Inc.(GPCR)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

37.06 USD

Average target price

75.7 USD

Spread / Average Target

+104.26%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
STRUCTURE THERAPEUTICS INC.	-9.08%	1.73B
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	118B
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B
BIONTECH SE	-8.14%	23.4B
ARGENX SE	-1.69%	21.78B
GENMAB A/S	-10.60%	18.09B
WUXI APPTEC CO., LTD.	-41.25%	16.72B
BEIGENE, LTD.	-15.33%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+5.80%	14.03B
SAREPTA THERAPEUTICS, INC.	+28.03%	11.67B

Bio Therapeutic Drugs